Price$0.78-0.13 (-14.38%)
2026-03-042026-06-05
News · 26 weeks32-75%
2025-12-142026-06-07
Mix2590d
- SEC Filings9(36%)
- Insider7(28%)
- Other6(24%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- ANALYSTH.C. Wainwright resumed coverage on Talphera with a new price targetH.C. Wainwright resumed coverage of Talphera with a rating of Buy and set a new price target of $3.00
- INSIDERChief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes4 - TALPHERA, INC. (0001427925) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)
- SECSEC Form 10-Q filed by Talphera Inc.10-Q - TALPHERA, INC. (0001427925) (Filer)
- SECTalphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- PRTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdateNEPHRO CRRT clinical study expected to be completed this yearCash and investments of $21.1 million at March 31, 2026Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ETSAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update."In early March, we announced the attainment of 50% enrollment in the NEPHRO CRRT study evaluating nafamostat. With continued steady enrollment, we have well exceeded this level,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Talphera Inc.SCHEDULE 13G/A - TALPHERA, INC. (0001427925) (Subject)
- PRTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.Webcast InformationThe webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted
- SECSEC Form DEFA14A filed by Talphera Inc.DEFA14A - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form DEF 14A filed by Talphera Inc.DEF 14A - TALPHERA, INC. (0001427925) (Filer)
- INSIDERSEC Form 4 filed by Angotti Vincent J.4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Asadorian Raffi4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Aslam Shakil4 - TALPHERA, INC. (0001427925) (Issuer)
- INSIDERSEC Form 4 filed by Dasu Badri N4 - TALPHERA, INC. (0001427925) (Issuer)
- SECSEC Form EFFECT filed by Talphera Inc.EFFECT - TALPHERA, INC. (0001427925) (Filer)
- SECSEC Form 424B7 filed by Talphera Inc.424B7 - TALPHERA, INC. (0001427925) (Filer)
- INSIDERSEC Form 4 filed by Angotti Vincent J.4 - TALPHERA, INC. (0001427925) (Issuer)
- PRTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for presentation at the 31st Annual International Conference on Advances in Critical Care Nephrology: AKI & CRRT 2026 to be held March 29-April 2, 2026 in San Diego.Poster Presentation 1Title: A Randomized, Placebo-Controlled, Multi-Center Study Of The Safety And Efficacy Of Niyad In Patients Undergoing Continuous Renal Replacement Therapy (CRRT) Who Cannot Tolerate Heparin Or Are At A Higher Risk of Ble
- SECSEC Form 10-K filed by Talphera Inc.10-K - TALPHERA, INC. (0001427925) (Filer)
- SECTalphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TALPHERA, INC. (0001427925) (Filer)
- PRTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatePreviously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 millionAll 12 clinical study sites now able to enroll patients to support an expected study completion in 2026Cash and investments of $20.4 million at December 31, 2025Virtual investor and analyst day with business updates to be held on Monday, March 23, 2026 at 11:00 am ETSAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced fourth quarter
- PRTalphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor and analyst event on Monday, March 23, 2026 at 11:00 AM ET featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera's NEPHRO CRRT study evaluating Niyad for continuous renal replacement therapy (CRRT). To register, click here.The experts will discuss their experience with CRRT, the anticoagulan
- INSIDERSEC Form 4 filed by Large owner Nantahala Capital Management, Llc4 - TALPHERA, INC. (0001427925) (Issuer)
- SECTalphera Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - TALPHERA, INC. (0001427925) (Filer)
- SECTalphera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - TALPHERA, INC. (0001427925) (Filer)
TLPH FAQ
6 questionsWhere does TLPH stock trade?
Talphera Inc. (TLPH) is listed on NASDAQ.What sector and industry is TLPH in?
Talphera Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Talphera Inc. go public?
Talphera Inc. (TLPH) completed its IPO in 2011.What are analysts saying about TLPH?
Talphera Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2026-06-05. Recent price targets range from $300.00 to $400.00.What companies are similar to TLPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TLPH side-by-side with any of them on Quantisnow.How can I track TLPH on Quantisnow?
Quantisnow aggregates Talphera Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLPH to receive live email and push alerts on every new disclosure.